drugset / Trial / NCT00568308
Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to determine if PI-88 is effective and safe in patients who have had surgery to remove primary liver cancer.
Timeline
- Start
- 2007-12
- Primary completion
- 2008-07
- Completion
- 2008-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | muparfostat | Other / unclassified | 160 mg | Subcutaneous |